Experimental Study On The Safety On Long-Term Symphysial Use Of Aspirin And Clopidogrel After Percutaneous Cardiology Intervention

Objective :To investigate the relationship between the ratio of platelet inhibition of long-term symphysial use of aspirin and clopidogrel after percutaneous coronary intervention(PCI) and bleeding.Method: 36 patients with non-ST-elevation acute coronary syndrome undergoing PCI were divided into control group (no bleeding) and test group (bleeding). After PCI therapy all patients took clopidogrel and aspirin for 9～12 months. Each group was observe by the ratio of platelet inhibition,PLT and the number of implanting frame. Platelet aggregation was determined by QX-200 platelet aggregation meter. the blood before administration as own control calculate the ratio of platelet inhibition at different time point after administration. the method: the ratio of platelet inhibition (% ) = (1 - platelet maximum aggregation impedance after administration / platelet maximum aggregation impedance before administration)×100%.Results: There were 9 patients in test group and 27 patients in control group. There was no serious bleeding in test group and there was no significant difference in ratio of platelet inhibition between two groups (P >0. 05), there was no significant difference in the number of implanting frame between two groups (P >0. 05), but there was significant difference in PLT(P< 0. 05).Conclusions:1. The Plateletcount are associated with bleeding in the patients who took clopidogrel and aspirin after PCI.2. the number of implanting frame are not associated with bleeding.3. the ratio of platelet inhibition was determined and calculated by QX-200 platelet aggregation meter out-of-service clinical unlethal bleeding monitoring after PCI at present4. long-term symphysial use of aspirin(100mg,s.i.d.) and clopidogrel(75mg,s.i.d.) after percutaneous coronary intervention(PCI) is safe and is not associated with bleeding.